Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 6 of 101, showing 5 Applications out of 502 total, starting on record 26, ending on 30

# Protocol No Study Title Investigator(s) & Site(s)

26.

ECCT/24/08/04   WHO A66045
    Heat-stable carbetocin for the treatment of postpartum haemorrhage: a phase III, randomized, double-blind, active controlled, multicountry, multicentre, non-inferiority trial   
Principal Investigator(s)
1. Zahida Qureshi
Site(s) in Kenya
1. Machakos county hospital (Machakos county)
2. Pumwani maternity hospital (Nairobi City county)
3. Kiambu level 5 hospital (Kiambu county)
 
View

27.

ECCT/24/08/02   S4V02
    Safety and immunogenicity of a second generation Shigella bioconjugate vaccine: a phase II randomized, controlled, and blinded study in 9-month-old infants   
Principal Investigator(s)
1. Richard Omore
Site(s) in Kenya
Siaya County Referral Hospital
 
View

28.

ECCT/24/06/03   PEARL RSVt Vaccine Study
    Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL   
Principal Investigator(s)
1. Dr Walter Otieno
Site(s) in Kenya
1. KEMRI-USAMRD-A Kombewa Clinical Research Centre (Kisumu county)
 
View

29.

ECCT/24/08/01   Evaluate clearance of HPV
    A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts   
Principal Investigator(s)
1. Fredrick Chite Asirwa
2. Kevin Makori Gesimba
Site(s) in Kenya
1. International Cancer Institute (ICI) (Uasin Gishu county)
2. Victoria Cancer Care and Research centre (Nyamira county)
 
View

30.

ECCT/24/06/01   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Raymond Scott McClelland
Site(s) in Kenya
1. Pwani Research Centre (Mombasa county)
 
View